Anvumetostat

N/A

Report date: 2026/04/06 20:01:48
NME

Base Information

Drug NameAnvumetostat
Drug Alias NameMTA Cooperative PRMT5 inhibitorAMG-193
ClassificationSmall molecules > Molecular Glue
Mechanisms of ActionProtein arginine methyltransferase 5 inhibitors
TargetsProtein arginine methyltransferase 5
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThoracic Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesAmgen Inc
China Registration ClassN/A

Develop Information

Active CompaniesAmgen Europe BvAmgen IncAmgen Biotechnology Consultation (Shanghai) Co Ltd
Inactive CompaniesN/A
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungThoracic Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A